SK2962003A3 - Biphenyl derivatives and the use thereof as integrin inhibitors - Google Patents
Biphenyl derivatives and the use thereof as integrin inhibitors Download PDFInfo
- Publication number
- SK2962003A3 SK2962003A3 SK296-2003A SK2962003A SK2962003A3 SK 2962003 A3 SK2962003 A3 SK 2962003A3 SK 2962003 A SK2962003 A SK 2962003A SK 2962003 A3 SK2962003 A3 SK 2962003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- formula
- group
- solvates
- groups
- physiologically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10041423A DE10041423A1 (de) | 2000-08-23 | 2000-08-23 | Biphenylderivate |
PCT/EP2001/008970 WO2002016328A1 (de) | 2000-08-23 | 2001-08-02 | Biphenylderivate und ihre verwendung als integrininhibitoren |
Publications (1)
Publication Number | Publication Date |
---|---|
SK2962003A3 true SK2962003A3 (en) | 2003-06-03 |
Family
ID=7653540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK296-2003A SK2962003A3 (en) | 2000-08-23 | 2001-08-02 | Biphenyl derivatives and the use thereof as integrin inhibitors |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040010023A1 (de) |
EP (1) | EP1311489A1 (de) |
JP (1) | JP2004524264A (de) |
KR (1) | KR20030022418A (de) |
CN (1) | CN1447799A (de) |
AU (1) | AU2001277561A1 (de) |
BR (1) | BR0113374A (de) |
CA (1) | CA2420208A1 (de) |
CZ (1) | CZ2003671A3 (de) |
DE (1) | DE10041423A1 (de) |
HU (1) | HUP0301784A3 (de) |
MX (1) | MXPA03001557A (de) |
NO (1) | NO20030813D0 (de) |
PL (1) | PL359668A1 (de) |
SK (1) | SK2962003A3 (de) |
WO (1) | WO2002016328A1 (de) |
ZA (1) | ZA200302256B (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
DE10127041A1 (de) * | 2001-06-02 | 2002-12-05 | Merck Patent Gmbh | Integrinantagonisten |
CN1964740A (zh) | 2004-04-02 | 2007-05-16 | 加利福尼亚大学董事会 | 治疗和预防与αVβ5整联蛋白有关的疾病的方法和组合物 |
BR112012001463A2 (pt) | 2009-07-24 | 2016-03-15 | Univ California | métodos e composições para tratar e prevenir doença associada à integrina alfavbeta5 |
RU2769702C2 (ru) | 2017-02-28 | 2022-04-05 | Морфик Терапьютик, Инк. | Ингибиторы интегрина avb6 |
MA47692A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
WO2019200202A1 (en) | 2018-04-12 | 2019-10-17 | Morphic Therapeutic, Inc. | Antagonists of human integrin (alpha4)(beta7) |
MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
CA3154269A1 (en) | 2019-10-16 | 2021-04-22 | Matthew G. Bursavich | Inhibiting human integrin .alpha.4.beta.7 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0880511A4 (de) * | 1996-01-16 | 1999-06-16 | Merck & Co Inc | Integrin-rezeptor-antagonisten |
AU751950B2 (en) * | 1997-11-24 | 2002-09-05 | Merck & Co., Inc. | Substituted beta-alanine derivatives as cell adhesion inhibitors |
CN1146541C (zh) * | 1999-02-20 | 2004-04-21 | 默克专利股份有限公司 | β-丙氨酸衍生物 |
-
2000
- 2000-08-23 DE DE10041423A patent/DE10041423A1/de not_active Withdrawn
-
2001
- 2001-08-02 BR BR0113374-8A patent/BR0113374A/pt not_active Application Discontinuation
- 2001-08-02 CA CA002420208A patent/CA2420208A1/en not_active Abandoned
- 2001-08-02 CN CN01814416A patent/CN1447799A/zh active Pending
- 2001-08-02 US US10/362,234 patent/US20040010023A1/en not_active Abandoned
- 2001-08-02 AU AU2001277561A patent/AU2001277561A1/en not_active Abandoned
- 2001-08-02 WO PCT/EP2001/008970 patent/WO2002016328A1/de not_active Application Discontinuation
- 2001-08-02 PL PL01359668A patent/PL359668A1/xx unknown
- 2001-08-02 JP JP2002521429A patent/JP2004524264A/ja active Pending
- 2001-08-02 HU HU0301784A patent/HUP0301784A3/hu unknown
- 2001-08-02 EP EP01955384A patent/EP1311489A1/de not_active Withdrawn
- 2001-08-02 MX MXPA03001557A patent/MXPA03001557A/es unknown
- 2001-08-02 KR KR10-2003-7002577A patent/KR20030022418A/ko not_active Application Discontinuation
- 2001-08-02 CZ CZ2003671A patent/CZ2003671A3/cs unknown
- 2001-08-02 SK SK296-2003A patent/SK2962003A3/sk unknown
-
2003
- 2003-02-21 NO NO20030813A patent/NO20030813D0/no unknown
- 2003-03-20 ZA ZA200302256A patent/ZA200302256B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1447799A (zh) | 2003-10-08 |
ZA200302256B (en) | 2004-07-26 |
DE10041423A1 (de) | 2002-03-07 |
US20040010023A1 (en) | 2004-01-15 |
MXPA03001557A (es) | 2003-06-06 |
NO20030813L (no) | 2003-02-21 |
CA2420208A1 (en) | 2003-02-21 |
EP1311489A1 (de) | 2003-05-21 |
PL359668A1 (en) | 2004-08-23 |
HUP0301784A2 (hu) | 2003-12-29 |
AU2001277561A1 (en) | 2002-03-04 |
NO20030813D0 (no) | 2003-02-21 |
CZ2003671A3 (cs) | 2003-06-18 |
KR20030022418A (ko) | 2003-03-15 |
JP2004524264A (ja) | 2004-08-12 |
WO2002016328A1 (de) | 2002-02-28 |
BR0113374A (pt) | 2003-07-08 |
HUP0301784A3 (en) | 2004-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003208325B2 (en) | 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin AVSS6 | |
JP4216071B2 (ja) | インテグリン阻害剤としての尿素およびウレタン誘導体 | |
SK2962003A3 (en) | Biphenyl derivatives and the use thereof as integrin inhibitors | |
SK11732001A3 (sk) | Deriváty beta-alanínu | |
US20030171304A1 (en) | Pyridine-2-yl-aminoalkyl carbonyl glycyl-$g(b)-alanine and derivatives thereof | |
SK13732003A3 (sk) | Inhibítory integrínov 'alfa'v'beta'6 | |
SK192002A3 (en) | Diacylhydrazine derivatives, process for the preparation and use thereof and pharmaceutical composition comprising same | |
US20040157902A1 (en) | Integrin antagonists | |
SK2952003A3 (en) | Biphenyl derivatives and the use thereof as integrin inhibitors | |
CZ20013704A3 (cs) | Dibenzoazulenové deriváty pro léčbu trombózy, osteoporózy, arteriosklerózy | |
KR20020012631A (ko) | 플루오렌 유도체 |